Lista de obras -

'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies.

artículo científico publicado en 2017

A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?

artículo científico publicado en 2013

A multinational observational study assessing insulin use: Understanding the determinants associated with progression of therapy

scientific article published on 24 January 2019

Alirocumab versus usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.

artículo científico publicado en 2018

Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study

artículo científico publicado en 2022

Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease

artículo científico publicado en 2019

Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial

artículo científico publicado en 2018

Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials.

artículo científico publicado en 2015

Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control

artículo científico publicado en 2019

Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS

scientific article published on 03 August 2006

Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?

artículo científico publicado en 2006

Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment - a clinical appraisal

artículo científico publicado en 2017

Clinical implications and outcomes of the ORION Phase III trials

scientific article published on 21 December 2020

Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial.

artículo científico publicado en 2017

Diabetic microvascular triopathy, smoking, and risk of cardiovascular events - Author's reply

artículo científico publicado en 2016

Dietary food patterns and glucose/insulin homeostasis: a cross-sectional study involving 24,182 adult Americans

artículo científico publicado en 2017

Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population.

artículo científico publicado en 2016

Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinica

artículo científico publicado en 2018

Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Pre-Specified Secondary End Points in ORION 1

scientific article published on 01 September 2018

Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study.

artículo científico publicado en 2017

Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials

artículo científico publicado en 2013

Efficacy and Safety of Pitavastatin in Children and Adolescents with Familial Hypercholesterolemia in Japan and Europe.

artículo científico publicado en 2017

Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial

artículo científico publicado en 2017

Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial.

artículo científico publicado en 2017

Epidemiology of familial hypercholesterolaemia: Community and clinical

artículo científico publicado en 2018

Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease.

artículo científico publicado en 2018

Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK.

artículo científico publicado en 2016

Ethnicity-specific association of BMI levels at diagnosis of type 2 diabetes with cardiovascular disease and all-cause mortality risk

artículo científico publicado en 2018

Feasibility Study Protocol: The Use of American Heart Association�s Cholesterol CarePlan to be Delivered as a Web Application on a Smartphone to Patients Prescribed Cholesterol Lowering Medication (Preprint)

artículo científico publicado en 2019

Guidelines in the USA, a viewpoint contrary to those guidelines in Europe, Canada, Britain and the International Atherosclerosis Society

artículo científico

IMPACT OF L-CARNITINE ON PLASMA LIPOPROTEIN(A) CONCENTRATIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

artículo científico publicado en 2016

Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials

artículo científico publicado en 2016

Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies

artículo científico publicado en 2015

Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms

artículo científico publicado en 2016

Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. A systematic review and meta-analysis of randomised controlled trials

artículo científico publicado en 2016

Improving the global care of familial hypercholesterolaemia: Starting the ball rolling

artículo científico publicado en 2018

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

scientific article published on 18 March 2020

Inclisiran for the treatment of dyslipidemia.

artículo científico publicado en 2018

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

artículo científico publicado en 2017

Investigation of Cardiovascular Health and Risk Factors Among the Diverse and Contemporary Population in London (the TOGETHER Study): Protocol for Linking Longitudinal Medical Records

scientific article published on 02 October 2020

Legacy benefits of blood glucose, blood pressure and lipid control in people with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?

artículo científico publicado en 2018

Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel

artículo científico publicado en 2017

Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel

artículo científico publicado en 2017

Lipids and Lipoproteins in Risk Prediction

artículo científico publicado en 2018

Long-term mortality after acute myocardial infarction among individuals with and without diabetes: A systematic review and meta-analysis of studies in the post-reperfusion era.

artículo científico publicado en 2016

Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coro

artículo científico publicado en 2017

Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials

article

Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study.

artículo científico publicado en 2017

New worldwide lipid guidelines.

artículo científico

Optimizing Cholesterol Treatment in Patients With Muscle Complaints.

artículo científico publicado en 2017

PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?

artículo científico publicado en 2017

Prediction of cardiovascular risk in patients with familial hypercholesterolaemia

artículo científico publicado en 2017

Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome ⬇️

artículo científico publicado el 22 de febrero de 2011

Relation of Fasting Triglyceride-Rich Lipoprotein Cholesterol to Coronary Artery Calcium Score (from the ELSA-Brasil Study).

artículo científico publicado en 2017

Response by Vallejo-Vaz et al to Letters Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/

artículo científico publicado en 2018

Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines.

artículo científico publicado en 2017

Review: Statins do not reduce mortality in patients with no history of cardiovascular disease ⬇️

artículo científico publicado el 21 de septiembre de 2010

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

artículo científico publicado en 2020

Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel

artículo científico publicado en 2015

Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

article

Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials

artículo científico publicado en 2015

Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants

artículo científico publicado en 2013

The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials

artículo científico publicado en 2017

The effects of statins on blood pressure in normotensive or hypertensive subjects--a meta-analysis of randomized controlled trials

artículo científico publicado en 2013

The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes

artículo científico publicado en 2019

The year in cardiology: cardiovascular prevention

artículo científico publicado en 2020

Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients

artículo científico

Transatlantic Lipid Guideline Divergence: Same Data But Different Interpretations

scientific article published on 23 October 2020

Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the Treating to New Targets (TNT) Trial.

artículo científico publicado en 2018

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

scientific article published on 18 March 2020

What imaging techniques should be used in primary versus secondary prevention for further risk stratification?

artículo científico publicado en 2017

Will genetic studies deliver the next generation of cardioprotective therapies?

artículo científico publicado en 2017

Lista de obras de

'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies.

A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?

A multinational observational study assessing insulin use: Understanding the determinants associated with progression of therapy

Alirocumab versus usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.

Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study

Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease

Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial

Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials.

Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control

Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS

Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?

Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment - a clinical appraisal

Clinical implications and outcomes of the ORION Phase III trials

Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial.

Diabetic microvascular triopathy, smoking, and risk of cardiovascular events - Author's reply

Dietary food patterns and glucose/insulin homeostasis: a cross-sectional study involving 24,182 adult Americans

Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population.

Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinica

Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Pre-Specified Secondary End Points in ORION 1

Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study.

Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials

Efficacy and Safety of Pitavastatin in Children and Adolescents with Familial Hypercholesterolemia in Japan and Europe.

Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial

Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial.

Epidemiology of familial hypercholesterolaemia: Community and clinical

Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease.

Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK.

Ethnicity-specific association of BMI levels at diagnosis of type 2 diabetes with cardiovascular disease and all-cause mortality risk

Feasibility Study Protocol: The Use of American Heart Association�s Cholesterol CarePlan to be Delivered as a Web Application on a Smartphone to Patients Prescribed Cholesterol Lowering Medication (Preprint)

Guidelines in the USA, a viewpoint contrary to those guidelines in Europe, Canada, Britain and the International Atherosclerosis Society

IMPACT OF L-CARNITINE ON PLASMA LIPOPROTEIN(A) CONCENTRATIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials

Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies

Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms

Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. A systematic review and meta-analysis of randomised controlled trials

Improving the global care of familial hypercholesterolaemia: Starting the ball rolling

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

Inclisiran for the treatment of dyslipidemia.

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

Investigation of Cardiovascular Health and Risk Factors Among the Diverse and Contemporary Population in London (the TOGETHER Study): Protocol for Linking Longitudinal Medical Records

Legacy benefits of blood glucose, blood pressure and lipid control in people with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?

Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel

Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel

Lipids and Lipoproteins in Risk Prediction

Long-term mortality after acute myocardial infarction among individuals with and without diabetes: A systematic review and meta-analysis of studies in the post-reperfusion era.

Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coro

Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials

Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study.

New worldwide lipid guidelines.

Optimizing Cholesterol Treatment in Patients With Muscle Complaints.

PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?

Prediction of cardiovascular risk in patients with familial hypercholesterolaemia

Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome ⬇️

Relation of Fasting Triglyceride-Rich Lipoprotein Cholesterol to Coronary Artery Calcium Score (from the ELSA-Brasil Study).

Response by Vallejo-Vaz et al to Letters Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/

Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines.

Review: Statins do not reduce mortality in patients with no history of cardiovascular disease ⬇️

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel

Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials

Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants

The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials

The effects of statins on blood pressure in normotensive or hypertensive subjects--a meta-analysis of randomized controlled trials

The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes

The year in cardiology: cardiovascular prevention

Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients

Transatlantic Lipid Guideline Divergence: Same Data But Different Interpretations

Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the Treating to New Targets (TNT) Trial.

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

What imaging techniques should be used in primary versus secondary prevention for further risk stratification?

Will genetic studies deliver the next generation of cardioprotective therapies?